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ABSTRACT
Objectives: To investigate whether associations of
smoking with depression and anxiety are likely to be
causal, using a Mendelian randomisation approach.
Design: Mendelian randomisation meta-analyses
using a genetic variant (rs16969968/rs1051730) as a
proxy for smoking heaviness, and observational meta-
analyses of the associations of smoking status and
smoking heaviness with depression, anxiety and
psychological distress.
Participants: Current, former and never smokers of
European ancestry aged ≥16 years from 25 studies in
the Consortium for Causal Analysis Research in
Tobacco and Alcohol (CARTA).
Primary outcome measures: Binary definitions of
depression, anxiety and psychological distress
assessed by clinical interview, symptom scales or self-
reported recall of clinician diagnosis.
Results: The analytic sample included up to 58 176
never smokers, 37 428 former smokers and 32 028
current smokers (total N=127 632). In observational
analyses, current smokers had 1.85 times greater odds
of depression (95% CI 1.65 to 2.07), 1.71 times greater
odds of anxiety (95% CI 1.54 to 1.90) and 1.69 times
greater odds of psychological distress (95% CI 1.56 to
1.83) than never smokers. Former smokers also had
greater odds of depression, anxiety and psychological
distress than never smokers. There was evidence for
Strengths and limitations of this study
▪ This is the largest Mendelian randomisation
study of the relationship between smoking and
depression and anxiety conducted to date.
▪ By using a genetic variant associated with
smoking heaviness as a proxy for smoking
heaviness, bias from confounding is minimised
and findings not affected by reverse causality.
▪ Measurement of depression and anxiety differed
across studies so we were unable to use a con-
sistent definition.
▪ While results are consistent with no causal asso-
ciation between smoking heaviness and depres-
sion or anxiety, we cannot rule out the
possibility of a small effect.
Taylor AE, et al. BMJ Open 2014;4:e006141. doi:10.1136/bmjopen-2014-006141 1
Open Access Research
group.bmj.com on August 9, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
positive associations of smoking heaviness with depression, anxiety
and psychological distress (ORs per cigarette per day: 1.03 (95% CI
1.02 to 1.04), 1.03 (95% CI 1.02 to 1.04) and 1.02 (95% CI 1.02 to
1.03) respectively). In Mendelian randomisation analyses, there was
no strong evidence that the minor allele of rs16969968/rs1051730
was associated with depression (OR=1.00, 95% CI 0.95 to 1.05),
anxiety (OR=1.02, 95% CI 0.97 to 1.07) or psychological distress
(OR=1.02, 95% CI 0.98 to 1.06) in current smokers. Results were
similar for former smokers.
Conclusions: Findings from Mendelian randomisation analyses do
not support a causal role of smoking heaviness in the development of
depression and anxiety.
INTRODUCTION
Smoking is highly comorbid with both depression and
anxiety across many different populations.1–9
Furthermore, there is evidence to suggest that tobacco
control interventions may not be as effective in popula-
tions with mental health conditions; for example, recent
trends in the USA suggest that, since 2004, smoking
rates have declined less rapidly in individuals with
anxiety than in the general population.10 Given the pro-
found public health burden of both tobacco-related
disease,11 and depression and anxiety,12 understanding
this relationship is of great importance.
Unfortunately, it is difﬁcult to infer causal links
between smoking and depression and anxiety from obser-
vational data, due to confounding. There may be factors
associated with both smoking and depression and
anxiety, such as other substance use (eg, alcohol), socio-
economic adversity and education which cannot be fully
accounted for in observational studies.13 In addition,
even if a causal association does exist, the direction of the
relationship between smoking and depression and
anxiety is unclear.14 Prospective studies have provided evi-
dence that depressive symptoms are associated with
increased likelihood of smoking initiation,2 7 15–17 while
smoking cessation appears to be associated with a short-
term increase in depressive symptoms during their quit
attempt among a subgroup of smokers, and these indivi-
duals have poor smoking cessation outcomes.18 This evi-
dence is consistent with the popular belief that cigarette
smoking can reduce anxiety and improve mood, particu-
larly among those experiencing anxiety or low mood (the
self-medication hypothesis). However, there is also a
growing body of evidence suggesting that smoking may
contribute to the development of these conditions2 7 19–
21 and that smoking cessation is associated with improve-
ments in mental health, including depression and
anxiety, compared to continued smoking.22
Plausible biological mechanisms through which consti-
tuents of tobacco smoke may cause depression and
anxiety have been described. In animal studies, for
example, there is evidence that nicotine administration
produces dysregulation in the hypothalamic-pituitary-
adrenal system, which leads to hypersecretion of cortisol
and changes in the activity of associated monoamine
neurotransmitters.23 These systems function to regulate
the biological and psychological reactions to stressors.
Similarly, human data have demonstrated elevated corti-
sol levels in smokers compared to non-smokers.24
Constituents of tobacco smoke inhibit the activity of
monoamine oxidase, enzymes that are involved in the
breakdown of monoamines (including dopamine, sero-
tonin and norepinephrine); this effect appears to nor-
malise following smoking cessation.25 Animal studies
also indicate that both drugs of abuse (including nico-
tine) and environmental stressors appear to trigger
changes in midbrain dopaminergic function.26
Consequently, prolonged smoking may act to sensitise
stress response systems, weakening adaptive coping
responses and making smokers more susceptible to emo-
tional distress in response to environmental stressors.
Mendelian randomisation methods allow us to investi-
gate causal relationships in humans by using genetic var-
iants as proxies for exposures of interest. The principle
of Mendelian randomisation relies on the basic (but
approximate) laws of Mendelian genetics (segregation
and independent assortment). When these principles
hold, genetic variants, at a population level, will not be
associated with the confounding factors that generally
distort conventional observational studies.27 28 In add-
ition, as an outcome measure cannot alter the genotype
that an individual is born with, these analyses should not
be biased by reverse causality. A genetic variant, single
nucleotide polymorphism (SNP) number rs16969968, in
the CHRNA5-CHRNA3-CHRNB4 (CHRNA5-A3-B4) nicoti-
nic receptor subunit gene cluster on chromosome 15
has demonstrated robust association with smoking heavi-
ness within smokers.29–32 The rs16969968 variant is func-
tional and leads to an amino acid change (D398N) in
the nicotinic receptor α5 subunit protein.33 The minor
(risk) allele of this variant is associated with an average
increase in smoking amount of one cigarette per day in
smokers, and even more strongly associated with
increases in cotinine (a metabolite of nicotine)
levels.31 34 35 However, given the known role of the
variant in altering receptor function,33 it is likely that
the greater variance explained for cotinine levels is due
to this measure better capturing total tobacco exposure,
and not because the variant directly affects nicotine
metabolism.31 There is also good evidence that the
rs16969968 variant, unlike smoking heaviness, does not
associate with confounding factors that may distort asso-
ciations with health outcomes, for example, socio-
economic status and education level.36 37
The rs16969968 variant (or its proxy rs1051730) has
been used as an instrument for smoking heaviness in
Mendelian randomisation studies to demonstrate that
smoking causally lowers body mass index38 and that
maternal smoking during pregnancy lowers offspring
birth weight39 (see ﬁgure 1 for an illustration of the
Mendelian randomisation approach). Using the
rs1051730 variant, two recent studies have applied
Mendelian randomisation to examine the causal
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relationship of smoking with depression and anxiety.37 38
In one large Norwegian population, the rs1051730
variant was not associated with depression or anxiety in
smokers40; in a British cohort, the rs1051730 variant was
associated with decreased depression during pregnancy
in women who smoked prior to pregnancy.41 These ﬁnd-
ings are not consistent with a causal role of smoking in
increasing depression or anxiety. To test the robustness
of these ﬁndings, we performed a Mendelian randomisa-
tion meta-analysis combining data from 25 studies
(n=127 632) in the consortium for Causal Analysis
Research in Tobacco and Alcohol (CARTA).
METHODS
Study populations
We used data on individuals aged ≥16 years and of self-
reported European ancestry from 25 studies from the
CARTA consortium: the 1958 Birth Cohort (1958BC), the
Avon Longitudinal Study of Parents and Children
(ALSPAC, including both mothers and children), the
British Regional Heart Study (BRHS), the British
Women’s Heart and Health Study (BWHHS), the
Caerphilly Prospective Study (CaPS), the Christchurch
Health and Development Study (CHDS), Cohorte
Lausannoise (CoLaus), the English Longitudinal Study of
Ageing (ELSA), the National FINRISK Study (FINRISK),
Generation Scotland: the Scottish Family Health Study
(GS:SFHS), Genomics of Overweight Young Adults
(GOYA) females, the Helsinki Birth Cohort Study
(HBCS), Health2006, Health2008, the second wave of the
Nord-Trøndelag health study (HUNT 2), Inter99, the
Northern Finland Birth Cohorts (NFBC1966 and
NFBC1986), the National Health and Nutrition
Examination Survey (NHANES), the MRC National
Survey of Health and Development (NSHD), the
Netherlands Twin Registry (NTR), Patch 2, the Rotterdam
Study, the Saguenay Youth Study-Parents (SYS-P) and the
Whitehall II study. Further details of these studies are pro-
vided in online supplementary material.
Genotype
Within each study, individuals were genotyped for one of
two SNPs in the CHRNA5-A3-B4 nicotinic receptor subunit
gene cluster, rs16969968 or rs1051730. These SNPs are in
perfect linkage disequilibrium with each other in
Europeans (R2=1.00 in HapMap 3, http://hapmap.ncbi.
nlm.nih.gov/) and therefore represent the same genetic
signal. Where studies had data available for both SNPs, we
used the SNP that was genotyped in the largest number of
individuals. Details of genotyping methods within each
study are provided in online supplementary material.
Measures of depression, anxiety and psychological
distress
Depression and anxiety were assessed by clinical inter-
view, symptom scales or self-reported recall of clinician
diagnosis (see table 1). As some of the scales do not dis-
tinguish between symptoms of depression and anxiety,
we used the term ‘psychological distress’ to refer a com-
posite phenotype.
To compare measures across studies, we created two
case deﬁnitions for each of depression, anxiety and psy-
chological distress (see table 2). According to case deﬁn-
ition 1, individuals were classiﬁed as depressed or
anxious if they self-reported clinician diagnosis of depres-
sion or anxiety, met clinical criteria for depression
(excluding bereavement where known) or anxiety, or
were above previously published cut points for depression
or anxiety on symptom scales. Individuals were classiﬁed
as having psychological distress if they met case deﬁnition
1 for depression or anxiety, or if they were above a cut
point on a general scale for psychiatric symptoms. As not
all scale measures used for assessing mental health have
published cut-offs for deﬁning cases, we created a second
deﬁnition. According to case deﬁnition 2, individuals
were classiﬁed as depressed or anxious if they were above
the 90th centile for the speciﬁc depression or anxiety
scales, and psychologically distressed if they were above
the 90th centile on either the depression or anxiety scales
or above the 90th centile on the general scales of psychi-
atric symptoms. Where both case deﬁnitions 1 and 2 were
available within a study, case deﬁnition 1 was used. Full
details of the measures and cut points used are provided
in online supplementary table S1.
For the majority of studies (k=17), diagnoses were
based on current depression and anxiety (at the time of
measurement). Where current diagnoses were not avail-
able, diagnoses of depression or anxiety in the previous
12 months or lifetime diagnoses were used. For lifetime
diagnoses, if information on age at ﬁrst diagnosis was
collected, individuals reporting diagnoses prior to
16 years of age were excluded.
Figure 1 Diagram of Mendelian randomisation analysis of
smoking and depression/anxiety. The genetic variant
rs16969968/rs1051730 is associated with smoking heaviness
but should not be associated with the confounders of the
association between smoking heaviness and depression/
anxiety. In addition, there is no pathway from depression and
anxiety to the genetic variant (reverse causality).
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Symptom scales were also used as continuous mea-
sures of depression, anxiety and psychological distress
(see online supplementary table S2). To compare across
studies, these were converted to z-scores within each
study. Most measures of depression, anxiety and psycho-
logical distress were strongly right skewed. However,
standard transformations (eg, log, square root) did not
greatly improve distributions in several of the samples.
Therefore, z-scores were constructed using the untrans-
formed data in all samples (z-score=(individual score
−sample mean)/sample SD).
Smoking status
Smoking status was self-reported (either by question-
naire or interview) at the same time as mental health
assessment for all studies, with the exception of 1958BC,
CoLaus and HBCS which used smoking status and
depression/anxiety data collected up to 3 years apart
(see online supplementary material). Individuals were
classiﬁed as never, former, current or ever (ie, current
and former combined) cigarette smokers. Where infor-
mation on smoking frequency was available, current
smokers were restricted to individuals smoking at least
one cigarette per day. Where information on pipe and
cigar smoking was available, individuals reporting being
current or former smokers of pipes or cigars but not
cigarettes were excluded from all analyses.
For studies with adolescent populations (ALSPAC chil-
dren and NFBC1986), analyses were restricted to current
daily smokers who reported smoking at least one
Table 1 Measures of depression, anxiety and psychological distress in the CARTA studies
Study Psychological Distress Depression Anxiety
1958BC CIS-R CIS-R CIS-R
ALSPAC children CIS-R CIS-R CIS-R
ALSPAC mothers EPDS or CCEI EPDS CCEI
BRHS Clinician diagnosis (lifetime)
BWHHS Clinician diagnosis (lifetime)
CaPS GHQ-30 STAI
CHDS CIDI (previous 12 months) CIDI (previous 12 months) CIDI (previous 12 months)
CoLaus DIGS DIGS DIGS
ELSA CES-D or clinician diagnosis of
anxiety
CES-D (8-item) Clinician diagnosis (lifetime)
FINRISK Clinician diagnosis (previous
12 months)
Generation
Scotland
GHQ-28 SCIDI/NP (Lifetime diagnosis)
GOYA females Clinician diagnosis (since giving
birth)
Clinician diagnosis (since giving
birth)
Clinician diagnosis (since giving
birth)
HBCS CES-D or STAI CES-D (20 items) STAI
Health2006 SCL-90-R SCL-90-R SCL-90-R
Health2008 SCL-90-R SCL-90-R SCL-90-R
HUNT HADS HADS HADS
Inter99 SCL-90-R SCL-90-R SCL-90-R
NFBC1966 SCL-25 SCL-25 SCL-25
NFBC1986 YSR YSR YSR
NHANES DIS (lifetime diagnosis)
NSHD GHQ-28
NTR ASR ASR ASR
Patch 2 SCID (lifetime diagnosis)
Rotterdam CES-D or M-CIDI CES-D (20 items) M-CIDI
SYS-P CES-D or DSM instrument CES-D (12 items) 10 question DSM-based
instrument
Whitehall II GHQ-30
All scales measure current depression and anxiety unless otherwise stated. Clinician diagnosis was assessed by self-reported recall in all
studies.
ALSPAC, Avon Longitudinal Study of Parents and Children; ASR, Adult Self Report; BC, Birth Cohort; BRHS, British Regional Heart Study;
BWHHS, British Women’s Heart and Health Study; CARTA, Causal Analysis Research in Tobacco and Alcohol; CCEI, Crown–Crisp
Experiential Index; CES-D, Centre for Epidemiologic Studies Depression; CHDS, Christchurch Health and Development Study; CIDI,
Composite International Diagnostic Interview; CIS-R, Computerised interview schedule-revised; CoLaus, Cohorte Lausannoise; DIGS,
Diagnostic Interview for Genetic Studies; DIS, Diagnostic Interview Schedule; ELSA, English Longitudinal Study of Ageing; EPDS, Edinburgh
Postnatal Depression Scale; GHQ, General Health Questionnaire; GOYA, Genomics of Overweight Young Adults; HADS, Hospital Anxiety
and Depression Scale; HBCS, Helsinki Birth Cohort Study M-CIDI, Munich version of CIDI; NHANES, National Health and Nutrition
Examination Survey; NSHD, National Survey of Health and Development; NTR, the Netherlands Twin Registry; SCID, Structured Clinical
Interview for DSM-III-R diagnosis; SCIDI/NP, Structured Clinical Interview for DSM-IV Axis disorders non-patient edition; SCL, symptoms
checklist; STAI, State Trait Anxiety Inventory; YSR, Youth Self Report.
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cigarette per day (current smokers) and individuals who
had never tried smoking (never smokers).
Smoking heaviness in current smokers, measured as
cigarettes smoked per day, was collected in some studies
as a continuous variable and in some studies as a cat-
egorical variable. Further details of the smoking mea-
sures collected within each study are provided in the
online supplementary material.
Statistical analysis
Analyses were conducted within each contributing study
using Stata or R software, following the same analysis
plan. Analyses were restricted to individuals with full
data on depression and anxiety outcomes, smoking
status and rs16969968/rs1051730 genotype.
Sex-adjusted and age-adjusted associations of smoking
status (never, former, current, ever) and smoking heavi-
ness with binary measures of depression, anxiety and
psychological distress were assessed using logistic regres-
sion. For the smoking status analysis, never smokers were
used as the reference group. The smoking heaviness
analysis was restricted to current daily smokers, and ORs
represent differences in odds of the outcome measure
per additional cigarette consumed per day. These ana-
lyses were restricted to studies with continuous measures
of cigarettes per day.
Within each study, genotype frequencies were tested
for deviation from Hardy-Weinberg equilibrium (HWE)
using a χ2 exact test. Mendelian randomisation analyses
of the association between rs16969968/rs1051730 and
binary measures of depression, anxiety and psycho-
logical distress were performed using logistic regression
and adjusted for age and sex. Analyses were performed
stratiﬁed by smoking status (never, former, current and
ever), because the variant only inﬂuences smoking
heaviness in individuals who smoke. The analysis in
never smokers is a test of a key assumption of Mendelian
randomisation: that the gene only operates on the
outcome through its effects on smoking heaviness
(ie, no pleiotropy). If rs16969968/rs1051730 only oper-
ates on an outcome measure through smoking heavi-
ness, no association should be observed in never
smokers. An additive genetic model was assumed, so
ORs represent the difference in odds of the outcome
per additional copy of the minor (risk) allele. As a sec-
ondary analysis, Mendelian randomisation analyses were
performed of the association of rs16969968/rs1051730
with z-scores of symptoms scales for depression, anxiety
and psychological distress using linear regression strati-
ﬁed by smoking status. These analyses were adjusted for
age and sex and additionally for use of depression or
anxiety medication where available. For studies with a
survey (NHANES) or family-based design (SYS-P),
appropriate methods were used to adjust SEs (see online
supplementary material for further information).
ALSPAC mothers and children were analysed as separate
samples but, as mothers and children were related, sensi-
tivity analyses were performed excluding each one of
these samples.
Results from individual studies were meta-analysed in
Stata (V.11) using the ‘metan’ command. Where there
was evidence of heterogeneity between studies
(I2>50%), both ﬁxed and random effects analyses were
performed. Within the Mendelian randomisation ana-
lyses, the Cochran Q statistic was used to test for interac-
tions between genotype and smoking status on the
outcome measures.
Analyses were also performed stratiﬁed by sex because
there is some evidence from observational studies that
the association between smoking and mental health out-
comes may differ by sex.42 43 Sex differences in the asso-
ciation between genotype and outcomes measures were
tested for using meta-regression after taking into
account potential differences by smoking status.
Table 2 Case definitions for depression, anxiety and psychological distress
Case definition 1 Case definition 2
Depression Self-report of clinical diagnosis
OR
Meeting clinical criteria for depression
OR
Scoring above published cut point on specific
depression scale
Scoring >90th centile on specific depression
scale
Anxiety Self-report of clinical diagnosis
OR
Meeting clinical criteria for anxiety disorders
OR
Scoring above published cut point on specific anxiety
scale
Scoring >90th centile on specific anxiety
scale
Psychological
distress
Depression or anxiety as defined above
OR
Scoring above published cut point on general scale for
psychiatric symptoms
Depression or anxiety as defined above
OR
>90th centile on general scale for psychiatric
symptoms
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RESULTS
Descriptive statistics
In total, data on up to 127 632 individuals were available
for analysis, including 58 176 never smokers, 37 428
former smokers and 32 028 current smokers. Overall,
45% of the combined study population was male. The
median age within the contributing studies ranged
between 16 and 68 years. The mean prevalence of
depression, anxiety and psychological distress (using
case deﬁnition 1) was 12.5% (range 6.1–37.5%), 10.2%
(range 2.6–19.9%) and 17.4% (range 8.9–27%), respect-
ively. Descriptive statistics for each of the study popula-
tions are provided in the online supplementary table S3.
The minor allele frequency for rs16969968/rs1051730
ranged between 0.31 and 0.39 (see online supplemen-
tary table S4). There was no strong evidence for devi-
ation from HWE in any of the studies (p values all
≥0.06).
Observational analysis
Levels of depression, anxiety and psychological distress
differed by smoking status (see ﬁgure 2). In age-adjusted
and sex-adjusted analyses, current smokers had 1.85
times (95% CI 1.65 to 2.07, p<0.001) greater odds of
depression, 1.71 times (95% CI 1.54 to 1.90, p<0.001)
greater odds of anxiety and 1.69 times (95% CI 1.56 to
1.83, p<0.001) greater odds of psychological distress
than never smokers. Former smokers had 1.22 times
(95% CI 1.14 to 1.30, p<0.001) greater odds of depres-
sion, 1.23 times (95% CI 1.12 to 1.36, p<0.001) greater
odds of anxiety and 1.17 times (95% CI 1.11 to 1.25,
p<0.001) greater odds of psychological distress than
never smokers.
Among smokers, smoking heaviness was positively asso-
ciated with levels of depression, anxiety and
psychological distress (ﬁgure 3). In age-adjusted and sex-
adjusted analyses, a one cigarette per day increase in
smoking heaviness was associated with a 1.03-fold (95%
CI 1.02 to 1.04, p<0.001) increase in the odds of having
depression, a 1.03-fold (95% CI 1.02 to 1.04, p<0.001)
increase in the odds of having anxiety and a 1.02-fold
(95% CI 1.02 to 1.03, p<0.001) increase in the odds of
having psychological distress.
As there was evidence of between-study heterogeneity
for analyses of both smoking status and smoking heavi-
ness, random effects meta-analyses are presented.
However, results from ﬁxed effects meta-analyses were
similar (data not shown). Individual study estimates for
observational analyses are provided in online supple-
mentary ﬁgures S1 and S2.
Mendelian randomisation analysis
There was no clear evidence that rs16969968/rs1051730
was associated with binary measures of depression in
never (OR per minor allele 1.02, 95% CI 0.97 to 1.06,
p=0.47), former (OR 1.00, 95% CI 0.95 to 1.05, p=0.99),
current (OR 1.00, 95% CI 0.95 to 1.05, p>0.99) or ever
(OR 1.01, 95% CI 0.98 to 1.05, p=0.58) smokers (see
ﬁgure 3). Similarly, there was no clear evidence that
rs16969968/rs1051730 was associated with binary mea-
sures of anxiety in former (OR 1.02, 95% CI 0.97 to
1.08, p=0.44), current (OR 1.02, 95% CI 0.97 to 1.07,
p=0.42) or ever (OR 1.03, 95% CI 0.99 to 1.07, p=0.16)
smokers. However, in never smokers there was some evi-
dence of a positive association between the minor allele
of rs16969968/rs1051730 and anxiety (OR 1.05, 95% CI
1.01 to 1.10, p=0.03). For psychological distress there was
a similar pattern, with no strong evidence for an associ-
ation between rs16969968/rs1051730 in smokers, but
some evidence of a positive association in never smokers
Figure 2 Age-adjusted and
sex-adjusted association of
smoking status with depression,
anxiety and psychological
distress.
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(OR 1.03, 95% CI 1.00 to 1.07, p=0.09). For all out-
comes, there was no clear statistical evidence for a differ-
ence in the effect of rs16969968/rs1051730 between
never, former and current smokers (p values for hetero-
geneity between never, former and current smokers
from Cochran Q test all >0.57). Individual study esti-
mates for observational analyses are provided in online
supplementary ﬁgure S3.
Results were similar for continuous measures of symp-
toms of depression, anxiety and psychological distress
(see online supplementary ﬁgures S4 and S5). There
was no clear evidence for associations of rs16969968/
rs1051730 with continuous outcomes in any of the
smoking categories.
Finally, there was no clear evidence for sex differences
in either observational or Mendelian randomisation
analyses for associations between smoking or smoking-
related genotype and depression or anxiety (data avail-
able on request).
DISCUSSION
In the largest Mendelian randomisation study on the
association of smoking with depression and anxiety con-
ducted to date, we found no evidence to suggest that
smoking causes either depression or anxiety. Despite
higher levels of depression, anxiety and psychological
distress in current and former smokers compared to
never smokers, and a positive association between the
number of cigarettes smoked per day and depression
and anxiety, there was no clear evidence for associations
between the CHRNA5-A3-B4 variant and these outcomes
in smokers. If heavier smoking were to cause
depression or anxiety, we would expect to see an
increased risk of depression or anxiety per copy of the
minor allele of rs16969968/rs1051730, which increases
smoking heaviness, in current smokers and potentially
also in former smokers, but no difference in risk for
never smokers. In our meta-analyses, ORs for the effect
of rs16969968/rs1051730 in current, former and ever
smokers were all close to the null, with the CIs for these
estimates all overlapping the null. In addition, we found
no evidence to suggest that the variant was differentially
associated with depression or anxiety according to
smoking status.
Our results are consistent with those of the two previ-
ous Mendelian randomisation studies, which did not
ﬁnd evidence that smoking increases depression or
anxiety40 or ante-natal depression.41 Both of these
studies were included in this meta-analysis and the
HUNT study made up more than half of the study
sample in some analyses. However, exclusion of either of
these samples did not make a substantial difference to
effect estimates (see online supplementary ﬁgures S6
and S7). These ﬁndings suggest that previous ﬁndings
linking smoking to higher levels of depression and
anxiety2 9 19 44 may be due to residual confounding, a
shared vulnerability to both mental disorders and
Figure 3 Age-adjusted and sex-adjusted observational and Mendelian randomisation analyses of association of smoking
heaviness with depression, anxiety and psychological distress. Observational analysis performed using random effects
meta-analysis and Mendelian randomisation analysis performed using fixed effects meta-analysis. Observational analysis
restricted to current smokers.
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smoking behaviour,45 or reverse causality (eg, if smokers
smoke in an attempt to alleviate the symptoms of depres-
sion or anxiety or depressed smokers ﬁnd it more difﬁ-
cult to quit). Numerous longitudinal studies have
reported that depressive symptoms in childhood and
adolescence are associated with increased risk of
smoking initiation or progression to tobacco depend-
ence.2 17 19 46–48 At the same time, smoking cessation
appears to be associated with an acute increase in
depressive symptoms among a subgroup of smokers, and
these individuals have poor smoking cessation out-
comes.18 Taken together, this suggests that people
experiencing depressive symptoms may smoke (or
relapse to smoking) in an attempt to self-medicate these
symptoms. A Mendelian randomisation study of the asso-
ciation of genetic variants for depression and anxiety
with smoking behaviour would be required to investigate
the self-medication hypothesis. However, genetic variants
robustly associated with depression and anxiety have yet
to be identiﬁed.49
Some caution should be taken in completely ruling
out an effect of this variant on depression and anxiety
within this analysis. The CIs for the associations of
rs16969968/rs1051730 with depression and anxiety in
current smokers overlap the estimates for the per cigar-
ette per day increase in ORs of depression and anxiety,
so we cannot conclusively say that the Mendelian ran-
domisation analysis results differ from the observational
results (ﬁgure 3). This is the most direct comparison
that we can make with observational estimates in our
data, given that the minor allele of rs16969968/
rs1051730 is associated with an average of one cigarette
per day increase in smoking heaviness.34 However, this
comparison may be problematic because cigarettes per
day, a self-reported measure of tobacco exposure, does
not take into account variation in smoking topography,
such as the amount of a cigarette an individual smokes
or the depth of inhalation.50 The CHRNA5-A3-B4 variant
is an instrument for lifetime tobacco exposure within
current smokers, and this is not fully captured by cigar-
ettes per day. It has been shown that rs16969968/
rs1051730 explains more of the variance in an objective
measure of tobacco exposure, cotinine (4%), than in
self-reported cigarettes per day (1%).31 35 This appears
to be why the variant shows a much stronger association
with lung cancer than predicted from the observed asso-
ciations with self-reported cigarettes per day.31 Therefore
if higher levels of smoking did cause depression or
anxiety, we might expect the effects of rs16969968/
rs1051730 to be considerably larger than those seen
observationally per cigarette per day. For the same
reason, we did not perform instrumental variable ana-
lysis to estimate the magnitude of the causal effect of
smoking heaviness on depression or anxiety. It has been
demonstrated that using cigarettes per day as an inter-
mediate variable in Mendelian randomisation analyses
using rs16969968/rs1051730 can lead to large biases in
causal effect size estimates.51
The rs16969968/rs1051730 variant associates with
smoking heaviness within smokers but is not an instru-
ment for smoking status (ever smoking vs never
smoking).29 Therefore we cannot rule out the possibility
that being a smoker, rather than smoking heaviness
could inﬂuence likelihood of depression or anxiety.
However, we do see an observational association
between smoking heaviness and depression and anxiety
(ﬁgure 3), and a dose-dependent relationship between
an exposure and an outcome strengthens support for a
causal association.52 We might therefore expect to
observe an association between rs16969968/rs1051730
and depression or anxiety if smoking were to cause
these conditions. Furthermore, while rs16969968/
rs1051730 is the strongest genetic contributor to
smoking behaviour identiﬁed to date,53 this variant only
explains a fraction of the estimated 50% of total vari-
ation in smoking behaviour within a population at any
one time that is due to genetic factors.54 Further signals
for smoking heaviness have been identiﬁed in the same
gene cluster,55 in other nicotinic receptor units and in
other genes, such as those related to nicotine metabol-
ism like CYP2A6.56 Combining these variants in genetic
risk scores for smoking behaviour in Mendelian random-
isation studies will be an important future direction for
validation of these results.
We would not expect to see an effect of rs16969968/
rs1051730 on depression or anxiety in never smokers,
because the variant is not associated with smoking heavi-
ness within these individuals. Thus, this group can be
used to test potential bias due to pleiotropy (that the
gene affects more than one exposure) in Mendelian ran-
domisation analyses.38 We did observe some evidence
for an association between the variant and anxiety in
never smokers, a ﬁnding previously reported by the
HUNT study.40 Removal of HUNT from this analysis did
not affect the point estimate, suggesting that this associ-
ation is not driven solely by the data from this study (see
online supplementary ﬁgure S6). However, using case
deﬁnition 2 (where available) for anxiety in preference
to case deﬁnition 1 slightly attenuated this association in
never smokers (see online supplementary ﬁgure S8).
While this may be a chance ﬁnding, it is possible that
rs16969968/rs1051730 or a variant in linkage disequilib-
rium with this variant, may affect anxiety directly, not
through tobacco consumption. There is some suggestion
from animal studies that nicotinic acetylcholine recep-
tors may play a role in anxiety (eg, mice lacking the α4
subunit show increases in anxiety-related behaviour57).
However, there is currently little evidence for this associ-
ation in humans, and rs16969968/rs1051730 has not
been identiﬁed in genome-wide association studies of
depression or anxiety to date.49 58 59
It is important to note that stratifying by the measured
exposure variable in Mendelian randomisation studies
can lead to collider bias.60 61 In this speciﬁc analysis, if
both the genetic variant and anxiety cause individuals to
smoke, then stratifying on smoking could, in theory,
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induce an association between the variant and anxiety.13
We do not think that collider bias is likely to be a major
issue in these analyses because rs16969968/rs1051730
does not appear to be associated with smoking initiation
in this sample (see online supplementary ﬁgure S9) or in
previous studies.29 30 There is, however, as reported previ-
ously in a few speciﬁc populations36 62 63 some evidence
that the minor allele of rs16969968/rs1051730 is asso-
ciated with smoking cessation; ORs of being a current
compared to a former smoker were 1.08-fold higher per
copy of the minor allele (95% CI 1.06 to 1.11) in this
sample.
Strengths and limitations
The key strength of this study is the large sample size,
using data on over 125 000 individuals from 25 different
populations. Despite this, we did not have the power to
rule out the possibility of a causal effect. A substantial
increase in sample size would be required to be conﬁdent
that what we observe is a true null association in smokers.
We hope that our estimates may be combined with those
of further studies addressing the same question in future
meta-analyses, to provide more deﬁnitive answers.
One of the main limitations is the use of broad deﬁni-
tions of depression and anxiety rather than clinical deﬁ-
nitions, which were not available in all studies. It is
possible that use of more precise phenotypic measures
of depression and anxiety based solely on clinical cri-
teria could yield stronger results because non-differential
misclassiﬁcation of a binary outcome is likely to attenu-
ate associations towards the null.2 64 However, we showed
the expected observational associations between
smoking and depression, anxiety and psychological dis-
tress. In addition, we used two case deﬁnitions and per-
formed a sensitivity analysis using case deﬁnition 2 in
preference (where both were available) which produced
similar results (see online supplementary ﬁgure S8).
Sensitivity analyses performed excluding lifetime deﬁni-
tions of depression or anxiety also produced similar
results (see online supplementary ﬁgure S10). Finally,
restricting our analyses to those studies with question-
naires based on clinical criteria or self-report of doctor
diagnosis produced consistent results, although these
analyses were underpowered (see online supplementary
ﬁgure S11).
Although we analysed depression and anxiety separ-
ately, these conditions are highly comorbid in the
general population65 66 and symptom scale question-
naires are not adequate to distinguish between
them.67 68 In addition, the deﬁnition of anxiety we used
encompassed general anxiety disorder, panic and
phobias. It is possible that these conditions have differ-
ent aetiologies.9 Therefore, we cannot make inferences
about speciﬁc anxiety disorders from these results.
Furthermore, the sample encompasses a wide age range,
so it is unlikely that this analysis would be able to
capture any age-speciﬁc effects of smoking on depres-
sion and anxiety.
CONCLUSION
In conclusion, our Mendelian randomisation analyses
do not support a causal role of smoking heaviness
among smokers in the development of depression and
anxiety. While we cannot directly address the question of
whether smoking initiation (ie, starting smoking) plays a
causal role in relation to these outcomes, we expect that
if it did we would also see a dose-dependent relationship
between smoking heaviness and depression and anxiety.
We see such an association in our observational analyses,
but no strong evidence for this in our Mendelian ran-
domisation analyses. Future research should focus on
the possible role of depression and anxiety in increasing
susceptibility to smoking. As larger genome-wide associ-
ation studies of depression and anxiety emerge, it is
likely that genetic variants will be identiﬁed that can be
utilised in Mendelian randomisation analyses for this
purpose.
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